Alumis Inc’s filing revealed that its Director Tananbaum James B. acquired Company’s shares for reported $0.12 million on May 02 ’25. In the deal valued at $4.62 per share,25,000 shares were bought. As a result of this transaction, Tananbaum James B. now holds 4,227,670 shares worth roughly $18.86 million.
Then, Tananbaum James B. bought 20,000 shares, generating $86,800 in total proceeds. Upon buying the shares at $4.34, the Director now owns 4,247,670 shares.
Before that, Foresite Labs, LLC bought 25,000 shares. Alumis Inc shares valued at $115,500 were divested by the 10% Owner at a price of $4.62 per share. As a result of the transaction, Foresite Labs, LLC now holds 4,227,670 shares, worth roughly $18.86 million.
Oppenheimer initiated its Alumis Inc [ALMS] rating to an Outperform in a research note published on January 30, 2025; the price target was $32. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in late October with a ‘”an Outperform”‘ rating. H.C. Wainwright began covering ALMS with “Buy” recommendation on October 17, 2024. Morgan Stanley started covering the stock on July 23, 2024. It rated ALMS as “an Overweight”.
Price Performance Review of ALMS
On Tuesday, Alumis Inc [NASDAQ:ALMS] saw its stock fall -15.05% to $4.46. Over the last five days, the stock has gained 2.53%. Alumis Inc shares have fallen nearly -43.26% since the year began. SMA at 50 days reached $5.31, while 200 days put it at $8.60.
Levels Of Support And Resistance For ALMS Stock
The 24-hour chart illustrates a support level at 4.14, which if violated will result in even more drops to 3.81. On the upside, there is a resistance level at 5.04. A further resistance level may holdings at 5.61. The Relative Strength Index (RSI) on the 14-day chart is 44.75, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.40, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 61.27%. Stochastics %K at 64.93% indicates the stock is a holding.
The most recent change occurred on July 23, 2024 when Leerink Partners began covering the stock and recommended ‘”an Outperform”‘ rating along with a $29 price target.
